| Company/Division name | AstraZeneca |
| Type of work | Manufacturing |
| Reshoring category: | Foreign Direct Investment |
| Year reshoring announced: | 2025 |
| Domestically, the work will be done: | In-house |
| Capital investment ($): | 445 |
| Country(ies) from which reshored: | Sweden,United Kingdom |
| City reshored to: | Coppell |
| State(s) reshored to: | TX |
| If relevant, work nearshored to: | - |
| Industry(ies): | Chemicals |
| Product(s) reshored | pharmaceuticals |
| What non-domestic negative factors made offshoring less attractive? | Supply chain interruption, Tariffs |
| What domestic positive factors made reshoring more attractive? | Skilled workforce availability/training |
